336 related articles for article (PubMed ID: 28174262)
1. Role of vascular normalization in benefit from metronomic chemotherapy.
Mpekris F; Baish JW; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1994-1999. PubMed ID: 28174262
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Vives M; Ginestà MM; Gracova K; Graupera M; Casanovas O; Capellà G; Serrano T; Laquente B; Viñals F
Int J Cancer; 2013 Nov; 133(10):2464-72. PubMed ID: 23649709
[TBL] [Abstract][Full Text] [Related]
3. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
Kareva I; Waxman DJ; Lakka Klement G
Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
[TBL] [Abstract][Full Text] [Related]
4. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
5. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
Ferdous T; Harada K; Kin T; Harada T; Ueyama Y
Int J Oncol; 2013 Jul; 43(1):271-9. PubMed ID: 23695365
[TBL] [Abstract][Full Text] [Related]
7. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
8. Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel.
Luan X; Guan YY; Lovell JF; Zhao M; Lu Q; Liu YR; Liu HJ; Gao YG; Dong X; Yang SC; Zheng L; Sun P; Fang C; Chen HZ
Biomaterials; 2016 Jul; 95():60-73. PubMed ID: 27130953
[TBL] [Abstract][Full Text] [Related]
9. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
10. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
11. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
Kareva I
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
[TBL] [Abstract][Full Text] [Related]
12. Metronomic therapy: chemotherapy revisited.
Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
[TBL] [Abstract][Full Text] [Related]
13. Metronomic gemcitabine targeted tumor vascular microenvironment decreases the population of CD133(+) cells in hepatocarcinoma xenografts.
Yi SY; Ruan J; Zhao L; Ke Y; Li XN
Cancer Biomark; 2014; 14(6):427-33. PubMed ID: 25335734
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
Ciccolini J; Barbolosi D; Meille C; Lombard A; Serdjebi C; Giacometti S; Padovani L; Pasquier E; André N
Cancer Res; 2017 Sep; 77(17):4723-4733. PubMed ID: 28655786
[TBL] [Abstract][Full Text] [Related]
15. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
Norrby K
APMIS; 2014 Jul; 122(7):565-79. PubMed ID: 24164171
[TBL] [Abstract][Full Text] [Related]
16. Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.
Bocci G; Fioravanti A; Orlandi P; Di Desidero T; Natale G; Fanelli G; Viacava P; Naccarato AG; Francia G; Danesi R
Neoplasia; 2012 Sep; 14(9):833-45. PubMed ID: 23019415
[TBL] [Abstract][Full Text] [Related]
17. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
18. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
Imai A; Zeitlin BD; Visioli F; Dong Z; Zhang Z; Krishnamurthy S; Light E; Worden F; Wang S; Nör JE
Cancer Res; 2012 Feb; 72(3):716-25. PubMed ID: 22158856
[TBL] [Abstract][Full Text] [Related]
19. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
20. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
